secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lifeward Ltd. (LFWD)
CIK:        0001607962
Form:       8-K
Filed at:   2026-05-15T12:00:26+00:00
Accession:  0001178913-26-002727
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M
--------------------------------------------------------------------------------

- Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.
- Net loss $10.8M ($6.70/share) vs $4.8M ($5.53/share) in Q1 2025; one-time $4.9M R&D charge.
- Unrestricted cash $11.4M at Mar 31, 2026, up from $2.2M at Dec 31, 2025; $6.5M from Oratech.
- Operating cash burn improved 33% YoY to $3.7M; ReWalk exoskeleton sales up 11% to $1.6M.
- Strategic transaction closed: $10M financing, Oratech acquisition with oral insulin Phase 2 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/0001178913-26-002727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607962/000117891326002727/zk2635349.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer